Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-10-09
2007-10-09
Wehbé, Anne M. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100
Reexamination Certificate
active
09300959
ABSTRACT:
The invention provides a method for stimulating an immune response by administering to a lymphoid tissue a nucleic acid molecule comprising an expression element operationally linked to a nucleic acid sequence encoding one or more heterologous epitopes. The heterologous epitope can be inserted into a complementarity-determining region of an immunoglobulin molecule. The invention also provides a nucleic acid molecule comprising a hematopoietic expression element operationally linked to a nucleic acid sequence encoding a heterologous polypeptide. The invention additionally provides a method of treating a condition by administering a nucleic acid molecule comprising a hematopoietic cell expression element operationally linked to a nucleic acid sequence encoding a heterologous polypeptide, wherein the nucleic acid molecule is targeted to a hematopoietic cell.
REFERENCES:
patent: 5508386 (1996-04-01), Zanetti et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5583202 (1996-12-01), Zanetti
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5658762 (1997-08-01), Zanetti et al.
patent: 5703055 (1997-12-01), Felgner et al.
patent: 5891432 (1999-04-01), Hoo
patent: 0 460 076 (1995-11-01), None
McCluskie et al. Molecular Medicine. 9: 267-300, Sep. 1999.
Verma et al. Nature. 389: 239-242, Sep. 1997.
Deonarain, Exp Opin Ther Patents, 8(1): 53-69, 1998.
Crystal, RG, Science, 270: 404-410, 1995.
Miller et al. FASEB J. 9: 190-199, Feb. 1995.
Eck et al, Goodman & Gilman's Pharmalogical Basis of Therapeutics. Chapter 8, McGraw-Hill, pp. 77-101, Sep. 1999.
Hurpin et. al.; The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity, 1998, Vaccine, vol. 16, No. 2/3: 208-215.
Maxwell et.al.; Expression of the Diphtheria Toxin A-Chain Coding Sequence Under the Control of Promoters and Enhancers from Immunoglobulin Genes as a Means of Directing Toxicity to B-Lymphoid Cells, 1991, Cancer Resarch51: 4299-4304.
Anderson et al., “Immune Response in Mice Following Immunization with DNA Encoding Fragment C of Tetanus Toxin,”Infect. Immunity, 64:3168-3173 (1996).
Banerji et al., “A Lymphocyte-Specific Cellular Enhancer is Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes,”Cell33:729-740 (1983).
Barry et al., “Protection against mycoplasma infection using expression-library immunization,”Nature, 377:632-635 (1995).
Billetta and Zanetti, “Ligand Expression Using Antigenization of Antibody: Principal and Methods,”Immuno Methods, 1:41-51 (1992).
Boyle et al., Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction,Nature, 392:408-411 (1998).
Chattergoon et al., “Specific Immune Induction Following DNA-Based Immunization Through In Vivo Transfection and Activation of Macrophages/Antigen-Presenting Cells,”J. Immunol.160:5707-5718 (1998).
Chen et al., “Idiotype-Cytokine Fusion Proteins as Cancer Vaccines. Relative Efficacy of IL-2, IL-4, and Granulocyte-Macrophage Colony-Stimulating Factor,”J. Immunol., 153:4775-4787 (1994).
Cohen, J., “Naked DNA Points Way to Vaccines,”Science, 259:1691-1692 (1993).
Condon et al., “DNA-based immunization by in vivo transfection of dendritic cells,”Nat. Med., 2:1122-1128 (1996).
Conry et al., “Immune Response to a Carcinoembryonic Antigen Polynucleotide Vaccine,”Cancer Res., 54:1164-1168 (1994).
Cox et al., “Bovine Herpesvirus 1: Immune Response in Mice and Cattle Injected with Plasmid DNA,”J. Virol.67:5664-5667 (1993).
Davis et al., “Direct Gene Transfer into Skeletal Muscle In Vivo: Factors Affecting Efficiency of Transfer and Stability of Expression,”Human Gene. Ther., 4:151-159 (1993).
Davis et al., Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen.,Vaccine12:1503-1509 (1994).
Davis et al., “Use of Plasmid DNA for Direct Gene Transfer and Immunization,”Ann. NY Acad. Sci., 772:21-29 (1995).
Davis et al., “DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost,”Vaccine, 14:910-915 (1996).
Disis et al., “Granulocyte-Macrophage Colony-Stimulating Factor: An Effective Adjuvant for Protein and Peptide-Based Vaccines,”Blood, 88:202-210 (1996).
Doe et al., “Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells,”Proc. Natl. Acad. Sci. USA, 93:8578-8583 (1996).
Donnelly et al., “DNA vaccines,”Annu. Rev. Immunol., 15:617-648 (1997).
Doolan et al., “Circumventing Genetic Restriction of Protection against Malaria with Multigene DNA Immunization: CD8+T-Cell-, Interferon γ-, and Nitric Oxide-Dependent Immunity,”J. Exp. Med., 183:1739-1746 (1996).
Eisenbraun et al., “Examination of Parameters Affecting the Elicitation of Humoral Immune Response by Particle Bombardment-Mediated Genetic Immunization,”DNA Cell Biol., 12:791-797 (1993).
Fynan, “DNA vaccines: Protective immunizations by parenteral, mucosal and gene-gun inoculations,”Proc. Natl. Acad. Sci. USA, 90:11478-11482 (1993).
Gerloni et al., “Activation of CD4 T Cells by Somatic Transgenesis Induces Genaralized Immunity of Uncommitted T Cells and Immunologic Memory,”J. Immunol., 162:3782-3789 (1999).
Gerloni et al., “Durable immunity and immunologic memory to a parasite antigen induced by somatic transgene immunization,”Vaccine, 16(2/3):293-297 (1998).
Gerloni et al., “Immunity toPlasmodium falciparummalaria sporozoites by somatic transgene immunization,”Nat. Biotech., 15:876-881 (1997).
Gerloni et al., “Somatic Transgene Immunization with DNA Encoding and Immunoglobulin Heavy Chain,”DNA and Cell Biol., 16(5):611-625 (1997).
Gerloni et al., “Immunological memory after somatic transgene immunization is positively affected by priming with GM-CSF and does not require bone marrow-derived dendritic cells,”Eur. J. Immunol., 28:1832-1838 (1998).
Gerloni et al., “DNA immunization in re/B-deficient mice discloses a role for dendritic cells in lgM→lgGl switch in vivo,”Eur. J. Immunol., 28:516-524 (1998).
Gilkeson et al., “Modulation of Renal Disease in Autoimmune NZB/NZW Mice by Immunization with Bacterial DNA,”J. Exp. Med., 183:1389-1397 (1996).
Gregoriadis , “Genetic Vaccines: Strategies for Optimization,”Pharm. Res., 15:661-670 (1998).
Hsu et al., “Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization,”Nat. Med.2:540-544 (1996).
Huygen et al., “Immunogenicity and protective efficacy of a tuberculosis DNA vaccine,”Nat. Med., 2:893-898 (1996).
Iwasaki et al., “The Dominant Role of Bone Marrow-Derived Cells in CTL Induction Following Plasmid DNA Immunization at Different Sites,”J. Immunol., 159:11-14 (1997).
Jones et al., “Potential Role of Granulocyte-Macrophage Colony-Stimulating Factor as Vaccine Adjuvant,”Eur. J. Clin. Microbiol. Infect. Dis., 13 Suppl. 2:S47-S53 (1994).
Manickan et al., “Genetic Immunization Against Herpes Simplex Virus. Protection is Mediated by CD4+T Lymphocytes1,”J. Immunol., 155:259-265 (1995).
Pertmer et al., “Influenza Virus Nucleoprotein-Specific Immunoglobulin G Subclass and Cytokine Responses Elicited by DNA Vaccination Are Dependent on the Route of Vector DNA Delivery,”J. Virol., 70:6119-6125 (1996).
Raz, et al., “Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses,”Proc. Natl. Acad. Sci. USA, 91:9519-9523 (1994).
Raz et al., “Preferential induction of a Th1immune response and inhibition of specific IgE antibody formation by plasmid DNA immuni
Needle & Rosenberg PC
Nevagen LLC
Wehbe Anne M.
LandOfFree
Somatic transgene immunization and related methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Somatic transgene immunization and related methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Somatic transgene immunization and related methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3874163